Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients (Breast Cancer Research and Treatment, (2017), 165, 2, (343-353), 10.1007/s10549-017-4328-z)

On Behalf Of The IrisTrial Participants

研究成果: Comment/debate査読

1 被引用数 (Scopus)

抄録

In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: ‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.

本文言語English
ページ(範囲)407
ページ数1
ジャーナルBreast Cancer Research and Treatment
167
1
DOI
出版ステータスPublished - 2018 1 1

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients (Breast Cancer Research and Treatment, (2017), 165, 2, (343-353), 10.1007/s10549-017-4328-z)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル